IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord ...
Stocktwits on MSN
IBRX stock jumps 6% pre-market on BCG update in Saudi Arabia – retail says share price is 'attractive'
ImmunityBio began discussions with SFDA to expand the use of ANKTIVA in combination with checkpoint inhibitors for multiple ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Investing.com -- ImmunityBio (NASDAQ:IBRX) stock surged 17.1% Wednesday after the European Commission granted conditional ...
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...
Intravesical bacillus Calmette-Guérin (BCG) with and without isoniazid (INH) is associated with outcomes superior to those intravesical epirubicin in patients with intermediate- and high-risk Ta and ...
Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...
The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer. FDA last night approved nogapendekin alfa inbakicept-pmln (NAI) ...
LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results